Inventor · disambiguated record
Markus Metz
Also filed as: METZ MARKUS
22 granted patents·25 pending applications·104 citations·filing 2004–2025
95Inventor score
Top patents by PatentIndex Score
47 records- 0196US11878024B2Tropomyosin-related kinase (Trk) inhibitorsGENZYME CORP·Filed 2022·Granted Jan 23, 2024·3 cites·6 claims
- 0296US11406644B2Tropomyosin-related kinase (TRK) inhibitorsGENZYME CORP·Filed 2020·Granted Aug 9, 2022·5 cites·21 claims
- 0395US12030853B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2020·Granted Jul 9, 2024·4 cites·14 claims
- 0494US12318392B2Tropomyosin-related kinase (trk) inhibitorsGENZYME CORP·Filed 2023·Granted Jun 3, 2025·1 cites·27 claims
- 0594US9174986B2Tropomyosin-related kinase (Trk) inhibitorsGENZYME CORP·Filed 2015·Granted Nov 3, 2015·13 cites·1 claims
- 0693US9067914B1Tropomyosin-related kinase (TRK) inhibitorsGENZYME CORP·Filed 2014·Granted Jun 30, 2015·15 cites·1 claims
- 0792US11661418B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2020·Granted May 30, 2023·4 cites·21 claims
- 0892US11008316B2Glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2017·Granted May 18, 2021·6 cites·2 claims
- 0992US10166239B2Tropomyosin-related kinase (Trk) inhibitorsGENZYME CORP·Filed 2017·Granted Jan 1, 2019·9 cites·33 claims
- 1092US9611265B2Tropomyosin-related kinase (TRK) inhibitorsGENZYME CORP·Filed 2015·Granted Apr 4, 2017·11 cites·10 claims
- 1190US11807641B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2020·Granted Nov 7, 2023·2 cites·18 claims
- 1289US12195427B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2022·Granted Jan 14, 2025·1 cites·18 claims
- 1387US11584714B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2019·Granted Feb 21, 2023·5 cites·13 claims
- 1486US12060349B2Glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2021·Granted Aug 13, 2024·1 cites·7 claims
- 1585US2025288595A1Tropomyosin-related kinase (trk) inhibitorsGENZYME CORP·Filed 2025·Application pending·0 cites
- 1684US11274108B2Colony stimulating factor-1 receptor (CSF-1R) inhibitorsGENZYME CORP·Filed 2016·Granted Mar 15, 2022·2 cites·15 claims
- 1784US7550484B2Chemokine receptor binding heterocyclic compounds with enhanced efficacyGENZYME CORP·Filed 2004·Granted Jun 23, 2009·19 cites·11 claims
- 1883US2024351980A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2024·Application pending·0 cites
- 1983US2025129020A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2024·Application pending·0 cites
- 2083US2025011323A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2024·Application pending·0 cites
- 2183US2024317682A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2024·Application pending·0 cites
- 2283US2024391917A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2024·Application pending·0 cites
- 2382US2025026749A1Glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2024·Application pending·0 cites
- 2479US12503477B2Colony stimulating factor-1 receptor (CSF-1R) inhibitorsGENZYME CORP·Filed 2024·Granted Dec 23, 2025·0 cites·6 claims
- 2575US12486278B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2023·Granted Dec 2, 2025·0 cites·19 claims
- 2675US2025243198A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2025·Application pending·0 cites
- 2775US2025197349A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2025·Application pending·0 cites
- 2874US2025376443A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2025·Application pending·0 cites
- 2972US2021261557A1Glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2021·Application pending·0 cites
- 3071US2025368604A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2025·Application pending·0 cites
- 3169US12110288B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2020·Granted Oct 8, 2024·0 cites·17 claims
- 3269US2022396588A1Colony stimulating factor-1 receptor (csf-1r) inhibitorsGENZYME CORP·Filed 2022·Application pending·0 cites
- 3368US2019183903A1Tropomyosin-related kinase (trk) inhibitorsGENZYME CORP·Filed 2018·Application pending·0 cites
- 3467US2025066383A1Pde 7 modulator compoundsOMEROS CORP·Filed 2024·Application pending·0 cites
- 3566US7491735B2Chemokine receptor binding compoundsGENZYME CORP·Filed 2004·Granted Feb 17, 2009·3 cites·6 claims
- 3665US2025122225A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2024·Application pending·0 cites
- 3765US2024279220A1Indole compounds and methods of useGENZYME CORP·Filed 2024·Application pending·0 cites
- 3864US2020048266A1Glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2019·Application pending·0 cites
- 3964US2024239784A1Indole compounds and methods of useGENZYME CORP·Filed 2024·Application pending·0 cites
- 4062US2024228499A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2023·Application pending·0 cites
- 4159US2009281308A1Chemokine receptor binding heterocyclic compounds with enhanced efficacyBRIDGER GARY J·Filed 2009·Application pending·0 cites
- 4257US2015210681A1Glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2013·Application pending·0 cites
- 4353US2016207933A1Glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2015·Application pending·0 cites
- 4452US7790747B2Chemokine receptor binding compoundsGENZYME CORP·Filed 2006·Granted Sep 7, 2010·0 cites·14 claims
- 4544US7498346B2Chemokine receptor binding compoundsGENZYME CORP·Filed 2005·Granted Mar 3, 2009·0 cites·12 claims
- 4644US2007066624A1Chemokine receptor binding compoundsANORMED INC·Filed 2006·Application pending·0 cites
- 4743US2010298366A1Chemokine receptor binding compoundsGENZYME CORP·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Markus Metz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →